Kymab: Sanofi gains access to antibody tech with Kymab acquisition
French pharma will receive global rights to phase 2a monoclonal antibody
Read full article »
CEO
Kymab is a biotechnology firm that develops and commercializes human antibody-based therapeutics for the treatment of infectious diseases.
Read more